Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting - Seite 2

Dynamics of Corneal Swelling during Corneal Collagen Cross-Linking in Progressive Keratoconus Patients

1:51 – 1:56 p.m., Miltos Balidis, Ph.D., MD
Customized Transepithelial Cross-Linking for Keratoconus: 2-Year Follow-up

2:11 – 2:16 p.m., Philip Dockery, MD
Corneal Cross-Linking for Patients with Progressive Keratoconus and Thin Corneas

3:47 – 3:55 p.m., Kenneth A. Beckman, MD
Update on Cross-Linking: Epi-on FDA Trial and Beyond

Key Corneal Health Posters:

• Brendan G. Cronin, FRANZCO, MBBS
  Oxygen-Supplemented and Topography-Guided Epi-on Corneal Cross-Linking with Pulsed Irradiation for Progressive Keratoconus

Key Corneal Health Course:
Saturday, May 6, 2023

• 8:00 – 9:30 a.m., Miguel Rechichi, Ph.D., MD
  Keratoconus State of the Art: New Cutting-Edge Treatments for Corneal Ectasia (IC-105)
  Co-instructors: Ashraf Armia Balamoun, MD, Miltiadis Balidis, PhD, MD, William B. Trattler, MD

Abstract information can be found at www.ascrs.org.

The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS annual meeting is planned by its program committee. ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

About iStent inject W Trabecular Micro-Bypass System (U.S.)

Indication for Use: The iStent inject W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.